Pfizer Inc. (NYSE:PFE) Shares Sold by Wesbanco Bank Inc.

Wesbanco Bank Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 249,261 shares of the biopharmaceutical company’s stock after selling 2,684 shares during the quarter. Wesbanco Bank Inc.’s holdings in Pfizer were worth $7,214,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Scarborough Advisors LLC purchased a new position in Pfizer during the fourth quarter worth approximately $124,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth $32,000. SageView Advisory Group LLC raised its position in shares of Pfizer by 2.2% in the 4th quarter. SageView Advisory Group LLC now owns 45,186 shares of the biopharmaceutical company’s stock worth $1,221,000 after buying an additional 973 shares during the period. Stonehearth Capital Management LLC boosted its holdings in Pfizer by 16.8% in the first quarter. Stonehearth Capital Management LLC now owns 10,463 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 1,506 shares during the last quarter. Finally, Cravens & Co Advisors LLC grew its position in Pfizer by 9.6% during the first quarter. Cravens & Co Advisors LLC now owns 19,135 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 1,681 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group boosted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Down 0.3 %

Shares of Pfizer stock opened at $29.08 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92. The business has a 50-day moving average of $29.02 and a 200-day moving average of $28.40. The company has a market capitalization of $164.78 billion, a PE ratio of -484.67, a P/E/G ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.78%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.